Carroll Financial Associates’s Insight Molecular Diagnostics IMDX Stock Holding History

Carroll Financial Associates’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-43	Closed	-$2K	–	1362
2018 Q3	$2K	Hold	43	–	–	﹤0.01%	1197
2018 Q2	$2K	Hold	43	–	–	﹤0.01%	1167
2018 Q1	$1K	Hold	43	–	–	﹤0.01%	1212
2017 Q4	$3K	Hold	43	–	–	﹤0.01%	1094
2017 Q3	$5K	Hold	43	–	–	﹤0.01%	984
2017 Q2	$4K	Hold	43	–	–	﹤0.01%	1031
2017 Q1	$5K	Hold	43	–	–	﹤0.01%	987
2016 Q4	$5K	Hold	43	–	–	﹤0.01%	943
2016 Q3	$4K	Hold	43	–	–	﹤0.01%	993
2016 Q2	$3K	Hold	43	–	–	﹤0.01%	1017
2016 Q1	$3K	Buy	+43	New	+$3.81K	﹤0.01%	999

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WJA

Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Carroll Financial Associates's IMDX Position: Q4 2018 in Review

Carroll Financial Associates sold out of Insight Molecular Diagnostics (IMDX) in Q4 2018, closing a stake of 43 shares — an estimated $2K sold.

Carroll Financial Associates first reported a position in IMDX in Q1 2016 and held it in 11 quarters. The position peaked at $5K in Q3 2017. 22 funds tracked by Wall St. Rank hold IMDX as of Q4 2018.

Carroll Financial Associates reported no remaining Insight Molecular Diagnostics position as of Q4 2018 after selling out during the quarter.
Carroll Financial Associates sold 43 Insight Molecular Diagnostics shares in Q4 2018, an estimated $2K.
Carroll Financial Associates first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 11 quarters.
Carroll Financial Associates's Insight Molecular Diagnostics position peaked at $5K in Q3 2017.
22 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2018.

Based on Carroll Financial Associates's 13F filing for Q4 2018, filed 11 Jan 2019.